INMB Q2 2025 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$24M

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$38M

Total Liabilities

$9M

Stockholders' Equity

$29M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$10M	-149.1%
Net Income	-$24M	-$10M	-151.0%